A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Phase 2 Completed 275 enrolled Atea Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Met primary endpoint

release “The Phase 2 study met its primary endpoints of efficacy and safety.” ateapharma.com ↗

Evaluation	Drug	Modality	Dose	Route
Subject	AT-527	Other / unclassified	550 mg	Oral
Subject	Ruzasvir	Other / unclassified	180 mg	Oral